New HIV pill dose could simplify treatment for kids across africa
NCT ID NCT05993767
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This study tested a new combination of three HIV medicines (dolutegravir, emtricitabine, and tenofovir alafenamide) in 53 children aged 28 days to 10 years in Africa. The goal was to find the right dose that keeps drug levels high enough to control HIV while being safe. Results will help create a single, easy-to-take tablet for children living with HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor College of Medicine Children's Foundation
Kampala, Uganda
-
Joint Research Centre
Kampala, Uganda
-
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe
Conditions
Explore the condition pages connected to this study.